William Mack & Associates
UTHR icon

William Mack & Associates’s United Therapeutics UTHR Stock Holding History

William Mack & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.08K Buy
+2
New +$1.03K ﹤0.01% 710

Other funds holding UTHR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

William Mack & Associates's UTHR Position: Q3 2026 in Review

William Mack & Associates opened a new position in United Therapeutics (UTHR) in Q3 2026: 2 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #710 among its holdings.

673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • William Mack & Associates held 2 shares of United Therapeutics worth $1.08K as of Q3 2026.
  • United Therapeutics was a new William Mack & Associates position in Q3 2026.
  • United Therapeutics made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #710 holding.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.